H. Michael Shepard is an American cancer researcher.
He holds a bachelor's degree from the University of California, Davis. He received a Ph.D. from the Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP) to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab (trade name: Herceptin).
Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.
Dr. Shepard holds over 25 US patents.
U.S. Patent 7,138,388 — Methods to treat autoimmune and inflammatory conditionsU.S. Patent 7,105,156 — Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cellsU.S. Patent 6,946,259 — Compositions and methods for treating cells having double minute DNAU.S. Patent 6,683,061 — Enzyme catalyzed therapeutic activationU.S. Patent 6,551,585 — Use of tumor necrosis factor as an adjuvantU.S. Patent 6,495,553 — Methods and compositions for overcoming resistance to biologic and chemotherapyU.S. Patent 6,399,063 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 6,387,371 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 6,348,352 — Methods for selectively transducing pathologic mammalian cells using a tumor suppressor geneU.S. Patent 6,339,151 — Enzyme catalyzed therapeutic agentsU.S. Patent 6,333,169 — HER2 extracellular domainU.S. Patent 6,331,524 — Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapyU.S. Patent 6,245,750 — Enzyme catalyzed therapeutic agentsU.S. Patent 6,165,464 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 6,159,706 — Application of enzyme prodrugs as anti-infective agentsU.S. Patent 6,015,567 — HER2 extracellular domainU.S. Patent 5,851,991 — Therapeutic use of the retinoblastoma susceptibility gene productU.S. Patent 5,837,520 — Method of purification of viral vectorsU.S. Patent 5,772,997 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 5,720,954 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 5,710,255 — Characterization of a novel anti-p110.sup.RB monoclonal antibodyU.S. Patent 5,677,171 — Monoclonal antibodies directed to the HER2 receptorU.S. Patent 4,963,354 — Use of tumor necrosis factor (TNF) as an adjuvantU.S. Patent 4,808,402 — Method and compositions for modulating neovascularization
